Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin
The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The...
Main Authors: | Berezin A.E., Sheychenko T.V., Berezina T.A., Vishnevaya N.V., Kovalenko N.V., Kulik Z.I., Мoiseenko I.А. |
---|---|
Format: | Article |
Language: | English |
Published: |
SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine"
2015-06-01
|
Series: | Medičnì Perspektivi |
Subjects: | |
Online Access: | http://medpers.dsma.dp.ua/issues/2015/N2/54-62.pdf |
Similar Items
-
Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin.
by: A. E. Berezin, et al.
Published: (2015-06-01) -
Clinical efficacy of pitavastatin
by: D. M Aronov, et al.
Published: (2018-03-01) -
Pitavastatin – a new inhibitor of the HMG-CoA reductase: peculiarities of clinical pharmacology and perspectives of its usage in treatment of cardiovascular diseases
by: Dzyak G.V., et al.
Published: (2013-12-01) -
Statins and diabetes: focus on pitavastatin
by: Soreiia A. Urazgildeeva
Published: (2020-09-01) -
New features correction of the dyslipidemia in patients with diabetes mellitus and metabolic cardiovascular risk factors
by: V. V. Syvolap, et al.
Published: (2014-04-01)